Santhera Pulls EU Filing For Failed DMD Candidate

End Of Road For Company’s DMD Idebenone Hopes, Patients 'Devastated'

 
• By Maureen Kenny

Swiss company Santhera's lengthy and problem-laden journey to repurpose its already marketed idebenone for use in Duchenne Muscular Dystrophy has ended in failure. The company has withdrawn its EU filing for the product following its announcement that it was halting development.

Link between genetics and various dystrophy disorders
DMD is one of the most common and severe forms of muscular dystrophy • Source: Shutterstock

More from Europe

More from Geography